Labcorp Receives FDA De Novo Marketing Authorization for PGDx elio™ plasma focus Dx
Go back to Labcorp Receives FDA De Novo Marketing Authorization for PGDx elio™ plasma focus Dx| Laboratory Corp. of America Holding (NYSE: LH) | Delayed: 258.59 +4.16 (1.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $254.43 | 52 Week High | $141.32 | |||
| Open | $257.68 | 52 Week Low | $97.79 | |||
| Day High | $260.32 | P/E | 41.37 | |||
| Day Low | $256.43 | EPS | $6.25 | |||
| Volume | 445,221 | |||||
